Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-0-30-253-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$37.14 million
Profitability
Miscellaneous
Employees98
Next Earnings Date7/25/2019 (Estimated)
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) posted its quarterly earnings data on Thursday, May, 30th. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.22. The biotechnology company had revenue of $8.75 million for the quarter, compared to analyst estimates of $7.47 million. Merus had a negative net margin of 75.71% and a negative return on equity of 39.46%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
6 brokers have issued twelve-month target prices for Merus' stock. Their predictions range from $16.00 to $35.00. On average, they anticipate Merus' stock price to reach $24.00 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
News articles about MRUS stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merus earned a news impact score of -4.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Merus.
Are investors shorting Merus?
Merus saw a drop in short interest in June. As of June 30th, there was short interest totalling 324,000 shares, a drop of 8.9% from the May 30th total of 355,700 shares. Based on an average daily trading volume, of 27,100 shares, the days-to-cover ratio is currently 12.0 days. Approximately 3.2% of the company's shares are short sold. View Merus' Current Options Chain.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Innoviva (INVA), Eidos Therapeutics (EIDX), Opko Health (OPK), Athenex (ATNX), Turning Point Therapeutics (TPTX), Corcept Therapeutics (CORT), Gossamer Bio (GOSS), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), ArQule (ARQL), Epizyme (EPZM), Aimmune Therapeutics (AIMT), Dicerna Pharmaceuticals (DRNA), Radius Health (RDUS) and Cara Therapeutics (CARA).
What other stocks do shareholders of Merus own?
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
- Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $15.00.
How big of a company is Merus?
Merus has a market capitalization of $341.27 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
